Reduced Serum Media
LS902 reduced-serum medium for adherent cells
LS902 is a low serum medium for adherent cells, suitable for the culture of Vero, 293, ST, Marc145, PK15, and other adherent cells. It promotes cell proliferation and virus replication. LS902 media is designed to support cell growth and proliferation while reducing the cost and variability associated with serum.Description
Performance
Features
3-5% serum addition
No adaptation required, supporting continuous passage
Generally suitable for common adherent cell lines
Used as both cell growth solution and maintenance solution
Advantages
3-5% serum addition at a controlled cost
Optional powder media for use in large-scale manufacturing with easy preparation procedures;
Powder media capable of a single batch size of 150,000 L;
Excellent inter-batch consistency (CPK*>1.33);
Full traceability by EU-certified ISO13485:2016 Quality Management System.
*CPK: Process Capability Index. CPK>1.33 indicates good process control and small inter-batch difference of products.

Order Information
Basal Medium
|
Application |
Product Name |
Cat. No. |
Size |
Form |
Product Instruction (pdf) |
Inquiries /Sample application |
|
Vero,293,ST,Marc145,PK15 and other adherent cells |
LS902 Adherent Cell Low-serum Medium | EXP0112704 |
200 L |
Powder |
||
| EXP0112703 |
10 L |
Powder |
Performance
Vaccines
In LS902 low-serum culture medium, PK-15/Vero/Marc-145/ST cells were inoculated at a density of 5×105 cells/25cm2 and subcultured every 48 hours. After adaptation to low-serum culture, the growth rate of PK-15/Vero/Marc-145/ST cells in LS902 low-serum culture medium was equal to or higher than that in DMEM+10% FBS culture system.

Documents
Reduced Serum Media
DownloadFAQ
Q1:What is low serum media?
Q2:Can BioEngine provide culture medium development service?
Q3:Is DMEM a complete medium?
Q4:What is a Marc145 cell?
Q5:What is in McCoy's 5A?
Q6:How to prevent mycoplasma contamination during cell culture?
Q7:What are the causes of cell clumping in suspension cultures and how to deal with it?
Previous
No InformationNext
No InformationHot Tags: reduced serum media, China reduced serum media manufacturers, suppliers, factory
Antibodies
In fed-batch process, CHO cells cultured in Eden CD CHO media demonstrate higher viable cell density (VCD) and protein production than competitors. On average, the antibody titers of various CHO cell lines cultured in Eden CD CHO media ranged from 2 to 11 g/L.

In the pulse perfusion process, CHO cells cultured in Eden CD CHO media demonstrated superior performance than competitive global brands. When VVD=1.0, volumetric productivity (Vp) can reach up to 2.2 g/L/day, and the cumulative product expression in 14 days can reach 19 g/L, 55% higher than global brand B. When VVD=2.0, Vp can reach up to 3.3g/L/day, and the cumulative product expression in 14 days can reach 25 g/L.

Brochures
| CHO Cell Medium |
FAQ
Q1: What is the packaging for BioEngine's powder media?
Q2: Can we seal the bag if there is leftover powdered medium?
Q3: What is the shelf life of BioEngine's Eden series CHO cell culture media, and how do you verify the expiration date?
Q4: Does BioEngine offer any regulators or additives for modulating antibody glycosylation?
Q5: Does BioEngine's CHO cell culture media contain hydrolysates, insulin, cytokines, or other components?
Q6: What are CHO media?
Q7: What are the differences between DMEM and RPMI?
1. Nutrient composition: DMEM (Dulbecco's Modified Eagle's Medium) and RPMI (Roswell Park Memorial Institute) have different nutrient compositions. DMEM contains higher levels of glucose, amino acids, vitamins, and sodium pyruvate, while RPMI has a lower glucose concentration and a different amino acid and vitamin composition.
2. pH: DMEM has a higher pH (7.4-7.6) compared to RPMI (7.2-7.4).
3. Usage: DMEM is a more general-purpose medium and can be used for a wide range of cell types, including adherent and non-adherent cells, while RPMI is typically used for the culture of immune cells such as lymphocytes and hybridomas.
4. Serum requirement: RPMI is often used with lower serum concentrations (e.g. 5-10%) than DMEM, which may require higher serum concentrations (e.g. 10-20%).
Overall, the choice between DMEM and RPMI depends on the specific cell type being cultured and the experimental conditions.
Q8: What is a fed-batch culture?
The goal of a fed-batch culture is to maximize cell growth and productivity while maintaining a stable culture environment. By controlling the rate and timing of nutrient addition, the culture can be kept in a state of controlled growth, avoiding the depletion of nutrients and accumulation of waste products that can limit growth and product formation in batch cultures. Additionally, the use of a fed-batch culture can allow for the accumulation of high cell densities and the optimization of production conditions, leading to higher yields and greater efficiency in bioprocesses.
Q9: What are the advantages of suspension cell cultures?
1. Scalability: Suspension cell cultures can be easily scaled up to produce large quantities of cells. This makes them particularly useful for biomanufacturing and the production of recombinant proteins.
2. Flexibility: Suspension cultures can be adapted to a wide range of culture conditions, such as pH, temperature, and nutrient availability. This allows for the optimization of cell growth and productivity.
3. Homogeneity: Suspension cultures provide a more homogeneous population of cells than adherent cultures, where cells may exhibit varying degrees of differentiation and proliferation.
4. Reduced risk of contamination: Suspension cultures are less prone to contamination by bacteria or fungi than adherent cultures, as there are no surfaces for microorganisms to adhere to.
5. Ease of harvesting: Cells in suspension culture can be easily harvested using centrifugation, filtration, or other methods. This simplifies downstream processing and reduces the risk of damage to the cells.
Overall, suspension cell culture offers several advantages over other types of cell culture, particularly in the context of large-scale biomanufacturing and the production of recombinant proteins.
Q10: What is gene therapy?
●Replacing a disease-causing gene with a healthy copy of the gene.
●Inactivating or deleting a disease-causing gene.
●Introducing a new or modified gene to help fight disease.
Gene therapy is a promising and innovative field of medicine that has potential applications for many diseases, such as cancer, genetic disorders, infectious diseases, and autoimmune diseases 23. However, gene therapy also faces many challenges and risks, such as safety, efficacy, ethical issues, and regulatory hurdles.
Gene therapy usually be delivered to the cells by virus vector, such as AAV, Adv and RV. BioEngine provides vigor series insect cell media for large scale AAV production."
Q11: Does BioEngine provides serum products, like FBS?
Previous
No InformationSend Inquiry
Provide high quality culture media for research institutions, biopharmaceutical companies and clinical trial institutions, etc.
I agree to receive other communications from BioEngine which may contain technical or marketing information from this organization. You can unsubscribe from these communications at any time.
By submitting this form, you are agreeing to the terms and conditions of our Privacy Policy
You Might Also Like









